Genotype-phenotype correlation for non-HLA disease associated risk alleles in multiple sclerosis

Neuroscience Letters

Volumn 526, Issue 1, 2012, Pages 15-19

  Harding, Katharine ^a,b   Ingram, Gillian ^b   Cossburn, Mark ^b   Hirst, Claire ^b   Pickersgill, Trevor ^b   Ben Shlomo, Yoav ^c   Robertson, Neil ^a,b  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Genetics; Multiple sclerosis; Prognosis

Indexed keywords

ADULT; ALLELE; ARTICLE; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; GENETIC RISK; GENOTYPE PHENOTYPE CORRELATION; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; ONSET AGE; PRIORITY JOURNAL; SCORING SYSTEM; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; ALLELES; FEMALE; GENETIC ASSOCIATION STUDIES; HLA ANTIGENS; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK;

EID: 84865626503     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2012.06.040     Document Type: Article

References (36)

1. Baranzini S.E., Wang J., Gibson R.A., Galwey N., Naegelin Y., Barkhof F., et al. Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis. Human Molecular Genetics 2009, 18(February (4)):767-778.
2. Coles A.J., Compston D.A.S., Selmaj K.W., Lake S.L., Moran S., Margolin D.H., et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. New England Journal of Medicine 2008, 359(October (17)):1786-1801.
3. Compston A., Coles A. Multiple sclerosis. Lancet 2008, 372(October (9648)):1502-1517.
4. Confavreux C., Vukusic S., Adeleine P. Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain 2003, 126(April (Pt 4)):770-782.
5. DeLuca G.C., Ramagopalan S.V., Herrera B.M., Dyment D.A., Lincoln M.R., Montpetit A., et al. An extremes of outcome strategy provides evidence that multiple sclerosis severity is determined by alleles at the HLA-DRB1 locus. Proceedings of the National Academy of Sciences of the United States of America 2007, 104(December (52)):20896-20901.
6. De Jager P.L., Jia X., Wang J., de Bakker P.I.W., Ottoboni L., Aggarwal N.T., et al. Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci. Nature Genetics 2009, 41(July (7)):776-782.
7. Eriksson M., Andersen O., Runmarker B. Long-term follow up of patients with clinically isolated syndromes, relapsing-remitting and secondary progressive multiple sclerosis. Multiple Sclerosis 2003, 9(June (3)):260-274.
8. Hensiek A.E., Sawcer S.J., Feakes R., Deans J., Mander A., Akesson E., et al. HLA-DR 15 is associated with female sex and younger age at diagnosis in multiple sclerosis. Journal of Neurology Neurosurgery and Psychiatry 2002, 72(February (2)):184-187.
9. Hensiek A.E., Seaman S.R., Barcellos L.F., Oturai A., Eraksoi M., Cocco E., et al. Familial effects on the clinical course of multiple sclerosis. Neurology 2007, 68(January (5)):376-383.
10. Hirst C., Ingram G., Swingler R., Compston D.A.S., Pickersgill T., Robertson N.P. Change in disability in patients with multiple sclerosis: a 20-year prospective population-based analysis. Journal of Neurology Neurosurgery and Psychiatry 2008, 79(October (10)):1137-1143.
11. Hutchinson M. Natalizumab: a new treatment for relapsing remitting multiple sclerosis. Therapy in Clinical Risk Management 2007, 3(June (2)):259-268.
12. IMSGC Risk alleles for multiple sclerosis identified by a genomewide study. New England Journal of Medicine 2007, 357(August (9)):851-862.
13. IMSGC Refining genetic associations in multiple sclerosis. Lancet Neurology 2008, 7(July (7)):567-569.
14. IMSGC The expanding genetic overlap between multiple sclerosis and type I diabetes. Genes Immunology 2009, 10(January (1)):11-14.
15. IMSGC Comprehensive follow-up of the first genome-wide association study of multiple sclerosis identifies KIF21B and TMEM39A as susceptibility loci. Human Molecular Genetics 2010, 19(March (5)):953-962.
16. IMSGC Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011, 476(August (7359)):214-219.
17. IMSGC Genome-wide association study of severity in multiple sclerosis. Genes Immunology 2011, 12(December (8)):615-625.
18. Jensen C.J., Stankovich J., Van der Walt A., Bahlo M., Taylor B.V., van der Mei I.A.F., et al. Multiple sclerosis susceptibility-associated SNPs do not influence disease severity measures in a cohort of Australian MS patients. PLoS One 2010, 5(4):e10003.
19. Jersild C., Svejgaard A., Fog T. HL-A antigens and multiple sclerosis. Lancet 1972, 1(June (7762)):1240-1241.
20. Kalman B., Albert R.H., Leist T.P. Genetics of multiple sclerosis: determinants of autoimmunity and neurodegeneration. Autoimmunity 2002, 35(July (4)):225-234.
21. Kamboh M.I., Barmada M.M., Demirci F.Y., Minster R.L., Carrasquillo M.M., Pankratz V.S., et al. Genome-wide association analysis of age-at-onset in Alzheimer's disease. Molecular Psychiatry 2011, (Internet). 2011 October 18 (cited 2011 October 25). Available from: http://www.ncbi.nlm.nih.gov/pubmed/22005931.
22. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983, 33(November (11)):1444-1452.
23. Lublin F.D., Reingold S.C. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996, 46(April (4)):907-911.
24. Marchini J., Donnelly P., Cardon L.R. Genome-wide strategies for detecting multiple loci that influence complex diseases. Nature Genetics 2005, 37(April (4)):413-417.
25. Marszalek J.R., Weiner J.A., Farlow S.J., Chun J., Goldstein L.S. Novel dendritic kinesin sorting identified by different process targeting of two related kinesins: KIF21A and KIF21B. Journal of Cell Biology 1999, 145(May (3)):469-479.
26. McDonald W.I., Compston A., Edan G., Goodkin D., Hartung H.P., Lublin F.D., et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Annals of Neurology 2001, 50(July (1)):121-127.
27. Mumford C.J., Wood N.W., Kellar-Wood H., Thorpe J.W., Miller D.H., Compston D.A. The British Isles survey of multiple sclerosis in twins. Neurology 1994, 44(January (1)):11-15.
28. Pankratz N., Nichols W.C., Elsaesser V.E., Pauciulo M.W., Marek D.K., Halter C.A., et al. Alpha-synuclein and familial Parkinson's disease. Movement Disorders 2009, 24(June (8)):1125-1131.
29. Polman C.H., Reingold S.C., Edan G., Filippi M., Hartung H.-P., Kappos L., et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the 'McDonald Criteria'. Annals of Neurology 2005, 58(December (6)):840-846.
30. Poser C.M., Paty D.W., Scheinberg L., McDonald W.I., Davis F.A., Ebers G.C., et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Annals of Neurology 1983, 13(March (3)):227-231.
31. Purcell S., Neale B., Todd-Brown K., Thomas L., Ferreira M.A.R., Bender D., et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. American Journal of Human Genetics 2007, 81(September (3)):559-575.
32. Robertson N.P., Clayton D., Fraser M., Deans J., Compston D.A. Clinical concordance in sibling pairs with multiple sclerosis. Neurology 1996, 47(August (2)):347-352.
33. Roxburgh R.H.S.R., Seaman S.R., Masterman T., Hensiek A.E., Sawcer S.J., Vukusic S., et al. Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity. Neurology 2005, 64(April (7)):1144-1151.
34. Tokumasa N., Suto A., Kagami S.-I., Furuta S., Hirose K., Watanbe N., et al. Expression of Tyk2 in dendritic cells is required for IL-12, IL-23, and IFN-gamma production and the induction of Th1 cell differentiation. Blood 2007, 110(July (2)):553-560.
35. Weinshenker B.G., Rice G.P., Noseworthy J.H., Carriere W., Baskerville J., Ebers G.C. The natural history of multiple sclerosis: a geographically based study. 4. Applications to planning and interpretation of clinical therapeutic trials. Brain 1991, 114(April (Pt 2)):1057-1067.
36. Westfall P.H., Young S.S. Resampling-based Multiple Testing: Examples and Methods for P-value Adjustment 1993, Wiley, New York.